EP Wealth Advisors LLC Sells 380 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

EP Wealth Advisors LLC cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9.1% during the 4th quarter, HoldingsChannel reports. The firm owned 3,811 shares of the company’s stock after selling 380 shares during the period. EP Wealth Advisors LLC’s holdings in Neurocrine Biosciences were worth $520,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NBIX. Caprock Group LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $236,000. Charles Schwab Investment Management Inc. grew its holdings in Neurocrine Biosciences by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company’s stock worth $104,089,000 after acquiring an additional 15,266 shares during the last quarter. Oakworth Capital Inc. bought a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $379,000. Avantax Advisory Services Inc. boosted its stake in shares of Neurocrine Biosciences by 11.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company’s stock valued at $395,000 after purchasing an additional 297 shares during the last quarter. Finally, Synergy Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at $996,000. 92.59% of the stock is owned by institutional investors.

Insider Activity

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the firm’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director now directly owns 37,491 shares in the company, valued at approximately $4,131,508.20. This trade represents a 44.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Matt Abernethy sold 2,558 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total transaction of $298,927.88. Following the transaction, the chief financial officer now directly owns 34,775 shares in the company, valued at $4,063,806.50. This represents a 6.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,953 shares of company stock worth $4,467,990 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Down 1.5%

Neurocrine Biosciences stock opened at $115.71 on Monday. The firm has a market capitalization of $11.45 billion, a price-to-earnings ratio of 35.17, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. The firm’s fifty day moving average price is $106.23 and its two-hundred day moving average price is $121.89. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Neurocrine Biosciences’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.20 EPS. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its board has authorized a stock repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NBIX. HC Wainwright reduced their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating on the stock in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Wednesday, March 26th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Bank of America reduced their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $162.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.